Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Susan Webb

Gynecology Knoxville, TN Medical Doctor

NPI 1518935311 CMS profile 833287

9330 Parkwest Blvd, Suite 409, Knoxville, TN 37923

Open in the dashboard

General payments

$6,617

353 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Susan Webb of Knoxville, TN is reported in the CMS Open Payments database as having received $6,617 across 353 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $198 11
2024 General $135 6
2023 General $804 41
2022 General $1,039 46
2021 General $1,498 85
2020 General $1,171 75
2019 General $1,772 89

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Susan Webb
  • Gynecology median
  • Middle half of Gynecology
  • National median

In program year 2025, general payments to Susan Webb were reported at $198. Among 1,279 Gynecology profiles paid that year, the median was $162 and the middle half received between $56 and $501.

Show as a table
Year Susan Webb Gynecology median Middle half National median
2019 $1,772 $199 $66–$472 $163
2020 $1,171 $114 $42–$287 $114
2021 $1,498 $141 $42–$430 $132
2022 $1,039 $173 $52–$532 $149
2023 $804 $170 $57–$501 $160
2024 $135 $157 $50–$424 $164
2025 $198 $162 $56–$501 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $952 48 payments
  2. Novo Nordisk Inc $947 51 payments
  3. Allergan Inc. $567 40 payments
  4. TherapeuticsMD, Inc. $499 28 payments
  5. AbbVie, Inc. $446 35 payments
  6. Vermillion, Inc. $343 5 payments
  7. Daiichi Sankyo Inc. $327 7 payments
  8. Lupin Inc. $326 19 payments
  9. Avion Pharmaceuticals $253 15 payments
  10. Mayne Pharma Inc. $226 12 payments
  11. Other $1,731 93 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,521 345 payments
  2. Education $96 8 payments
Products named General payments · program years 2019–2025
  1. PREMARIN $1,070 54 payments
  2. Saxenda $507 32 payments
  3. Wegovy $430 17 payments
  4. MYFEMBREE Genitourinary (Sexual Health);Womens Health $389 19 payments
  5. OVA1 $343 5 payments
  6. VRAYLAR $317 3 payments
  7. INJECTAFER $282 4 payments
  8. NURTEC ODT $273 13 payments
  9. SOLOSEC $257 15 payments
  10. MYFEMBREE Hormone Therapy $217 12 payments
  11. Other $3,395 224 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

11

Median for Obstetrics & Gynecology: 65

Drug cost

$2,627

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

100%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Premarin Estrogens, Conjugated Brand 11 $2,627

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Veozah
  • Astellas Pharma US Inc $46
$46 — —
BOTOX
  • AbbVie, Inc. $27
$27 — —
SLYND
  • Exeltis, USA Inc. $18
$18 — —
PREMARIN
  • PFIZER INC. $17
$17 11 —
MYFEMBREE
  • PFIZER INC. $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

353 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gynecology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record